CHICAGO, March 10, 2020 -- AltaThera Pharmaceuticals, LLC, a hospital specialty pharmaceutical company focused on commercializing innovative drugs aimed at improving outcomes and reducing hospital costs, announces that the US Food and Drug Administration (FDA) has approved new indications for Sotalol IV in AFib patients. "The new indications for Sotalol IV represent a significant advance that decreases length of stay for new patients starting sotalol for AFib," said Jodi Devlin, AltaThera's CEO. "We are proud to continue our leadership in cardiac and critical care medicine as we work diligently to bring innovative therapies to patients in the United States. We are on target with our commercial launch preparations and expect to launch Sotalol IV's new indications in the second half of the year."